Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE:301520)

China · Delayed Price · Currency is CNY

37.02

-0.93 (-2.45%)

At close: Jun 2, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Clinical Research Services	217.94M	303.67M	243.69M	188.12M	149.73M
Clinical Research Services Growth	-28.23%	24.62%	29.54%	25.64%	50.40%
Pharmaceutical Research Services	21.81M	38.52M	60.45M	50.02M	45.94M
Pharmaceutical Research Services Growth	-43.39%	-36.28%	20.86%	8.87%	50.37%
Other	34.43M	36.90M	37.67M	22.64M	4.76M
Other Growth	-6.68%	-2.04%	66.36%	375.58%	59.46%
Total	274.18M	379.09M	341.81M	260.78M	200.44M
Total Growth	-27.67%	10.91%	31.07%	30.10%	50.60%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China	274.18M	379.09M	341.81M	260.78M	211.09M
China Growth	-27.67%	10.91%	31.07%	23.54%	51.72%
Total	274.18M	379.09M	341.81M	260.78M	211.09M
Total Growth	-27.67%	10.91%	31.07%	23.54%	51.72%

Source: S&P Global Market Intelligence.